Insider Selling: Stemline Therapeutics Inc (STML) COO Sells 13,547 Shares of Stock

Stemline Therapeutics Inc (NASDAQ:STML) COO Kenneth Hoberman sold 13,547 shares of Stemline Therapeutics stock in a transaction that occurred on Tuesday, January 8th. The shares were sold at an average price of $10.15, for a total transaction of $137,502.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Kenneth Hoberman also recently made the following trade(s):

  • On Monday, November 26th, Kenneth Hoberman sold 26,296 shares of Stemline Therapeutics stock. The shares were sold at an average price of $11.85, for a total transaction of $311,607.60.

Shares of Stemline Therapeutics stock opened at $9.89 on Friday. Stemline Therapeutics Inc has a fifty-two week low of $7.82 and a fifty-two week high of $20.55. The company has a market capitalization of $329.14 million, a price-to-earnings ratio of -3.36 and a beta of 0.78.



Stemline Therapeutics (NASDAQ:STML) last issued its earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.06). Equities research analysts expect that Stemline Therapeutics Inc will post -2.81 EPS for the current fiscal year.

Institutional investors have recently modified their holdings of the business. Bank of America Corp DE boosted its position in Stemline Therapeutics by 97.8% in the second quarter. Bank of America Corp DE now owns 20,548 shares of the biopharmaceutical company’s stock valued at $329,000 after buying an additional 10,159 shares in the last quarter. Nexthera Capital LP boosted its position in Stemline Therapeutics by 4.0% in the third quarter. Nexthera Capital LP now owns 582,070 shares of the biopharmaceutical company’s stock valued at $9,662,000 after buying an additional 22,553 shares in the last quarter. Point72 Asset Management L.P. boosted its position in Stemline Therapeutics by 20.9% in the third quarter. Point72 Asset Management L.P. now owns 260,000 shares of the biopharmaceutical company’s stock valued at $4,316,000 after buying an additional 45,000 shares in the last quarter. BlueMountain Capital Management LLC boosted its position in Stemline Therapeutics by 175.9% in the third quarter. BlueMountain Capital Management LLC now owns 23,537 shares of the biopharmaceutical company’s stock valued at $391,000 after buying an additional 15,006 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its position in Stemline Therapeutics by 8.7% in the second quarter. Schwab Charles Investment Management Inc. now owns 59,025 shares of the biopharmaceutical company’s stock valued at $948,000 after buying an additional 4,700 shares in the last quarter. Hedge funds and other institutional investors own 64.20% of the company’s stock.

A number of research analysts recently issued reports on STML shares. ValuEngine raised shares of Stemline Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, November 23rd. HC Wainwright set a $38.00 price objective on shares of Stemline Therapeutics and gave the company a “buy” rating in a research note on Wednesday, November 21st. Roth Capital set a $33.00 price objective on shares of Stemline Therapeutics and gave the company a “buy” rating in a research note on Wednesday, November 14th. BidaskClub cut shares of Stemline Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 2nd. Finally, Piper Jaffray Companies set a $20.00 price objective on shares of Stemline Therapeutics and gave the company a “buy” rating in a research note on Friday, December 21st. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $26.00.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Dakota Financial News and is the property of of Dakota Financial News. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at https://dakotafinancialnews.com/2019/01/12/insider-selling-stemline-therapeutics-inc-stml-coo-sells-13547-shares-of-stock.html.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.

Recommended Story: What is the 52-week high/low?

Insider Buying and Selling by Quarter for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply